Biogen Inc (BIIB)

Add to Watchlists
Create an Alert
Quickflows
264.80 -5.41  -2.00% NASDAQ Oct 22, 16:00 264.99 +0.19  +0.07% After-Hours: 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All BIIB News

News

View All Events

Events

Date Type Description
02/03/2022 Earnings Results Q4 2021 Earnings Results
02/03/2022 08:00 EST Earnings Calls Q4 2021 Earnings Call
10/20/2021 Earnings Results Q3 2021 Earnings Results
10/20/2021 08:00 EST Earnings Calls Q3 2021 Earnings Call
07/22/2021 Earnings Results Q2 2021 Earnings Results
07/22/2021 08:00 EST Earnings Calls Q2 2021 Earnings Call
06/02/2021 AGM 2020 Annual General Meeting
04/22/2021 Earnings Results Q1 2021 Earnings Results
04/22/2021 08:00 EST Earnings Calls Q1 2021 Earnings Call
02/03/2021 Earnings Results Q4 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 11.10B
Total Expenses (TTM) 9.364B
Net Income (TTM) 1.546B

Balance Sheet View Statement

Total Assets (Quarterly) 23.81B
Total Liabilities (Quarterly) 12.92B
Shareholders Equity (Quarterly) 10.43B

Cash Flow Statement View Statement

Cash from Operations (TTM) 2.434B
Cash from Investing (TTM) -617.40M
Cash from Financing (TTM) -2.497B

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
  • URL: http://www.biogen.com
  • Investor Relations URL: https://investors.biogen.com
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Feb. 03, 2022
  • Last Earnings Release: Oct. 20, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 264.80
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
BBH VanEck Biotech ETF 4.61%
VPMCX Vanguard PRIMECAP Inv 4.22%
HQL Tekla Life Sciences Investors 4.00%
PKW Invesco BuyBack Achievers ETF 3.85%
VHCOX Vanguard Capital Opportunity Inv 3.45%
HQH Tekla Healthcare Investors 3.38%
VPCCX Vanguard PRIMECAP Core Inv 3.32%
IBB iShares Biotechnology ETF 3.19%
POGRX PRIMECAP Odyssey Growth 3.05%
VGHCX Vanguard Health Care Inv 2.98%
POAGX PRIMECAP Odyssey Aggressive Growth 2.83%
LRGF iShares MSCI USA Multifactor ETF 1.05%

Comparables

Edit
IONS Ionis Pharmaceuticals Inc
MRNA Moderna Inc
LLY Eli Lilly and Co
PFE Pfizer Inc
BMY Bristol-Myers Squibb Co

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.